Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 4
2013 2
2014 3
2015 3
2016 7
2017 4
2018 4
2019 6
2020 6
2021 11
2022 12
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Clément K, et al. Among authors: kuhnen p. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
Pharmacotherapy in Childhood Obesity.
Kühnen P, Biebermann H, Wiegand S. Kühnen P, et al. Horm Res Paediatr. 2022;95(2):177-192. doi: 10.1159/000518432. Epub 2021 Jul 19. Horm Res Paediatr. 2022. PMID: 34351307 Free article. Review.
Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment.
Lechner L, Opitz R, Silver MJ, Krabusch PM, Prentice AM, Field MS, Stachelscheid H, Leitão E, Schröder C, Fernandez Vallone V, Horsthemke B, Jöckel KH, Schmidt B, Nöthen MM, Hoffmann P, Herms S, Kleyn PW, Megges M, Blume-Peytavi U, Weiss K, Mai K, Blankenstein O, Obermayer B, Wiegand S, Kühnen P. Lechner L, et al. Among authors: kuhnen p. Sci Transl Med. 2023 Jul 19;15(705):eadg1659. doi: 10.1126/scitranslmed.adg1659. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467315
Pharmacological treatment strategies for patients with monogenic obesity.
Kühnen P, Wiegand S, Biebermann H. Kühnen P, et al. J Pediatr Endocrinol Metab. 2020 Jul 3:/j/jpem.ahead-of-print/jpem-2020-0129/jpem-2020-0129.xml. doi: 10.1515/jpem-2020-0129. Online ahead of print. J Pediatr Endocrinol Metab. 2020. PMID: 32619193 Review.
Melanocortin 4 receptor mutations become common.
Kühnen P, Biebermann H, Krude H. Kühnen P, et al. Cell Metab. 2021 Aug 3;33(8):1512-1513. doi: 10.1016/j.cmet.2021.07.003. Cell Metab. 2021. PMID: 34348096 Free article.
Aberrant expression of agouti signaling protein (ASIP) as a cause of monogenic severe childhood obesity.
Kempf E, Landgraf K, Stein R, Hanschkow M, Hilbert A, Abou Jamra R, Boczki P, Herberth G, Kühnapfel A, Tseng YH, Stäubert C, Schöneberg T, Kühnen P, Rayner NW, Zeggini E, Kiess W, Blüher M, Körner A. Kempf E, et al. Among authors: kuhnen p. Nat Metab. 2022 Dec;4(12):1697-1712. doi: 10.1038/s42255-022-00703-9. Epub 2022 Dec 19. Nat Metab. 2022. PMID: 36536132 Free PMC article.
60 results